NEUPNeuphoria Therapeutics Inc. Common Stock
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia. Its lead product…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Scancell sees high demand in retail share offer, seals £15.7m from UK investors Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF, FRA:SCP) confirmed the UK leg of its equity funding has raised gross proceeds of £15.7 million after strong retail demand prompted the cancer immunotherapy developer to increase the size of its retail offer. The retail offer raised £2.7... | ||
 SMALL-CAP MOVERS: Nasdaq-bound Scancell catches the eye as AIM's headcount falls to 612 Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF, FRA:SCP) saw its shares drop 27% this week, but the movement obscures the real story, which is a largely positive one for investors. It may take the market a while to process some transformational changes that will see the oncology research... | ||
Neuphoria Therapeutics Agrees to All-Share Takeover by Scancell Neuphoria Therapeutics (NEUP) and Scancell Holdings said Thursday they have agreed to an all-stock m | MMT Newswires | |
 Scancell to join Nasdaq through Neuphoria merger and $89 million funding package Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF, FRA:SCP), the Oxford-based cancer immunotherapy developer listed on London's junior AIM market, has agreed an all-share merger with US biotech Neuphoria Therapeutics that will give it a Nasdaq listing and access to American investors. The combined... | ||